Rosenborg Staffan, Nordström Annica, Almquist Tora, Wennberg Lars, Bárány Peter
Department of Clinical Pharmacology , Karolinska University Hospital , Stockholm , Sweden ; Department of Renal Medicine , Karolinska University Hospital , Stockholm , Sweden.
Department of Clinical Pharmacology , Karolinska University Hospital , Stockholm , Sweden.
Clin Kidney J. 2014 Apr;7(2):151-155. doi: 10.1093/ckj/sfu015. Epub 2014 Mar 14.
Tacrolimus (Prograf) is a key drug in the immunosuppressive treatment of renal transplant patients. Since the expiration of the patent for Prograf, generic preparations have been approved in Europe as bioequivalence has been shown in healthy volunteers. However, few studies have investigated whether patients can be successfully converted from Prograf to generic tacrolimus. Tacrolimus drug costs are by far the largest single item in the total drug expenditure for patients with renal disease in the Stockholm area. Considerable reductions in drug costs could be achieved if generic tacrolimus were to be used. The aim of this quality assurance study was to evaluate whether a switch from Prograf to generic tacrolimus (Tacrolimus Sandoz) could be safely performed in renal transplant patients. It further aimed to investigate changes of renal function (measured in estimated glomerular filtration rate, eGFR), need for dose changes and to calculate potential drug cost savings as a result of the conversion.
We planned to recruit at least 50 patients. Plasma creatinine levels and trough concentrations of tacrolimus were collected from patients with renal transplants at three occasions during treatment with Prograf and three times after conversion to Tacrolimus Sandoz. The eGFR was calculated before and after the conversion.
Sixty-three of 67 enrolled patients (69% males, age 28-80 years) are included in this analysis. The ratio of mean trough concentrations of tacrolimus after comparison with before conversion was 1.02 (90% confidence interval 0.95-1.09). Fourteen patients experienced a change in tacrolimus levels >20% compared with baseline, no patients changed >20% in eGFR. The drug cost saving per daily dose was 33.40 SEK (∼€3.60, -23%).
Stable kidney transplant patients treated with Prograf can be converted to Tacrolimus Sandoz if trough concentrations of tacrolimus and plasma creatinine levels are closely monitored. The conversion brought savings, despite costs for extra monitoring.
他克莫司(普乐可复)是肾移植患者免疫抑制治疗中的关键药物。自普乐可复专利到期以来,由于已在健康志愿者中证明了生物等效性,其仿制药制剂已在欧洲获得批准。然而,很少有研究调查患者是否能成功从普乐可复转换为他克莫司仿制药。在斯德哥尔摩地区,他克莫司药物成本是肾病患者总药物支出中迄今为止最大的单项。如果使用他克莫司仿制药,可实现药物成本的大幅降低。这项质量保证研究的目的是评估肾移植患者从普乐可复转换为他克莫司仿制药(山德士他克莫司)是否可以安全进行。它还旨在研究肾功能的变化(以估计肾小球滤过率,即eGFR衡量)、剂量调整的必要性,并计算转换带来的潜在药物成本节省。
我们计划招募至少50名患者。在使用普乐可复治疗期间的三个时间点以及转换为山德士他克莫司后的三个时间点,收集肾移植患者的血浆肌酐水平和他克莫司谷浓度。在转换前后计算eGFR。
67名入组患者中的63名(69%为男性,年龄28 - 80岁)纳入本分析。转换后与转换前相比,他克莫司平均谷浓度的比值为1.02(90%置信区间0.95 - 1.09)。14名患者的他克莫司水平与基线相比变化>20%,没有患者的eGFR变化>20%。每日剂量的药物成本节省为33.40瑞典克朗(约合3.60欧元,-23%)。
如果密切监测他克莫司谷浓度和血浆肌酐水平,接受普乐可复治疗的稳定肾移植患者可以转换为山德士他克莫司。尽管有额外监测的成本,但转换带来了节省。